Evidence map›Paper›PMID 25952030›Full record

ArticleCardiovascular diabetology2015

Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy.

Hideaki Jinnouchi, Kazunori Morita, Takahiro Tanaka, Ayami Kajiwara, Yuki Kawata, Kentaro Oniki, Junji Saruwatari, Kazuko Nakagawa, Koji Otake, Yasuhiro Ogata and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Hideaki JinnouchiDivision of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan. hideaki@jinnouchi.or.jp.
Kazunori MoritaDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. 133y3107@st.kumamoto-u.ac.jp.
Takahiro TanakaDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. 102p1027@st.kumamoto-u.ac.jp.
Ayami KajiwaraDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. 132y3102@st.kumamoto-u.ac.jp.
Yuki KawataDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. 109p1015@st.kumamoto-u.ac.jp.
Kentaro OnikiDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. oniken@kumamoto-u.ac.jp.
Junji SaruwatariDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. junsaru@gpo.kumamoto-u.ac.jp.
Kazuko NakagawaDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, 862-0973, Kumamoto, Japan. kazukon@gpo.kumamoto-u.ac.jp.
Koji OtakeJapanese Red Cross Kumamoto Health Care Center, Kumamoto, Japan. 101p1022@st.kumamoto-u.ac.jp.
Yasuhiro OgataJapanese Red Cross Kumamoto Health Care Center, Kumamoto, Japan. 103p1035@st.kumamoto-u.ac.jp.
Akira YoshidaJinnouchi Clinic, Diabetes Care Center, Kumamoto, Japan. akira.y@jinnouchi.or.jp.
Seiji HokimotoDivision of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan. shokimot@kumamoto-u.ac.jp.
Hisao OgawaDivision of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan. ogawah@kumamoto-u.ac.jp.
Kumamoto University · JPJapanese Red Cross Kumamoto Hospital · JPKumamoto University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the clinical relevance of a common variant, rs4820599, in the γ-glutamyltransferase (GGT)1 gene, associated with the serum GGT level, in Japanese type 2 diabetes mellitus (T2DM) subjects.

methodsWe conducted a retrospective longitudinal study (4.9 ± 2.5 years) including 352 T2DM patients (T2DM subjects) and a cross-sectional study including 796 health screening program participants (general subjects). A real-time TaqMan allelic discrimination assay was used to identify the genotypes. Risk factors for a high brachial-ankle pulse wave velocity (baPWV) (≥1750 cm/sec) or diabetic retinopathy (DR) were determined using a generalized estimating equations approach, receiver operating characteristic (ROC) analysis or Cox proportional hazards model, etc.

resultsThe frequency of the GGT1 G allele was 20.8% in the T2DM subjects, and no associations were found between the GGT1 genotype and risk of T2DM. The mean log GGT values in the T2DM and general subjects were significantly higher among G allele carriers than non-carriers. The G allele and a low HDL-C level were identified to be risk factors for a high baPWV in the T2DM subjects [odds ratio (OR) 1.80, P = 0.008; OR 1.71, P = 0.03; respectively), and a significant interactive effect between these factors was found on the risk of a high baPWV and DR. The HDL-C level at baseline was a significant predictor of a high baPWV only in G allele carriers according to the ROC analysis. This result regarding baPWV in the T2DM subjects was replicated in the general population. Meanwhile, the GGT1 genotype was not associated with the risk of DR, although it affected the principal factors involved in the risk of DR, and a low HDL-C level was also found to be a risk factor for DR only in G allele carriers.

conclusionsWe herein describe for the first time the significant interactive effects of the GGT1 G allele and a low HDL-C level on a high baPWV and DR. These findings may encourage future clinical trials comparing the efficacy of agents increasing the HDL-C levels among the GGT1 genotypes. However, well-designed studies in larger cohorts are needed to confirm our results.

Indexed as

AgedCross-Sectional StudiesDiabetes Mellitus, Type 2Diabetic AngiopathiesFemalegamma-GlutamyltransferaseGenetic VariationHumansLipoproteins, HDLLongitudinal StudiesMaleMiddle AgedRetrospective Studiesgamma-Glutamyltransferasegamma-glutamyltransferase, humanLipoproteins, HDL

Identifiers

PMID25952030
PMCPMC4428095
OpenAlexW1593818502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.